Integrating viral hepatitis management into the emergency department: A further step towards viral hepatitis elimination

被引:3
|
作者
Llaneras, Jordi [1 ]
Ruiz-Cobo, Juan Carlos [2 ]
Rando-Segura, Ariadna [3 ,4 ]
Barreira-Diaz, Ana [2 ]
Dominguez-Hernandez, Raquel [5 ]
Rodriguez-Frias, Francisco [4 ,6 ]
Campins, Magda [7 ]
Colom, Joan [8 ]
Casado, Miguel Angel [4 ,5 ]
Blanco-Grau, Albert [6 ]
Banares, Juan [2 ]
Monforte, Arnau
Falco-Roget, Anna [9 ]
Ruiz, Lourdes [2 ]
Meza, Beatriz [1 ]
Pumarola, Tomas [3 ]
Riveiro-Barciela, Mar [2 ,4 ]
Esteban, Rafael [2 ,4 ]
Buti, Maria [2 ,4 ,10 ]
机构
[1] Hosp Univ Vall Dhebron, Emergency Dept, Barcelona, Spain
[2] Hosp Univ Vall Dhebron, Liver Unit, Barcelona, Spain
[3] Hosp Univ Vall Dhebron, Microbiol Dept, Barcelona, Spain
[4] Inst Salud Carlos III, CIBEREHD, Madrid, Spain
[5] Pharmacoecon & Outcomes Res Iberia PORIB, Madrid, Spain
[6] Hosp Univ Vall Dhebron, Biochem Dept, Barcelona, Spain
[7] Hosp Univ Vall Dhebron, Epidemiol Serv, Barcelona, Spain
[8] Hlth Dept, Publ Hlth Agcy Catalonia, Gen Subdirect Prevent Control & Care Addict HIV ST, Barcelona, Spain
[9] Hosp Univ Vall Dhebron, Infect Dis Dept, Barcelona, Spain
[10] Vall Dhebron 119, Barcelona 08035, Spain
关键词
HBV; HCV; HDV; Mass screening; Emergency service; Cost-effectiveness analysis; ECONOMIC-EVALUATION; COST-EFFECTIVENESS; C VIRUS;
D O I
10.1016/j.jhepr.2023.100932
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Many people with HCV and HBV infection are unaware of their condition, particularly at-risk and vulnerable populations who face barriers for screening and linkage to care. Emergency departments are often their only point of contact with the health system. Methods: This is a prospective study investigating HBsAg and HCV antibody testing, with reflex testing for HDV antibodies and HCV RNA, in adults attending an emergency department and requiring a blood test. Positive cases were linked to care. A cost-effectiveness analysis was performed. Results: From February 2020 to February 2022, a total of 17,560 individuals were screened. HBsAg was detected in 91 (0.5%), HCV RNA in 128 (0.7%), and HDV antibodies in two (0.01%) individuals. Nearly 40% of positive cases were unaware of their condition. Linkage to care was achieved in 42 of 56 HBsAg-positive and 45 of 69 HCV RNA-positive participants who were candidates for referral. HCV and HBV screening vs. no screening yielded 1.06 and 0.42 additional quality-adjusted life-years, respectively, with incremental cost-utility ratios of euro7,629 and-euro147 per quality-adjusted life-year gained, respectively, and proved even more cost-effective in patients with hepatitis C aged 40-70 years. Conclusions: On emergency department screening for hepatitis B, C, and D in Barcelona, the prevalence of HBsAg was 0.5% and HCV RNA 0.7%, approximately threefold higher than that observed in the general population. This strategy diagnosed patients with active HCV infection and no risk factors, who would not have been screened according to the current rec-ommendations. Screening and linkage to care of viral hepatitis is cost-effective in this setting. Impact and implications: We evaluated the performance and cost-effectiveness of a viral hepatitis screening programme implemented in an emergency department, which aimed to identify and link to care people living with hepatitis B and C. Our findings reveal a threefold higher prevalence of hepatitis B and C than in the general Spanish population, possibly attributable to the role of the emergency department as the main healthcare gateway for vulnerable populations, who have a higher prevalence of viral hepatitis. Risk factors for viral hepatitis could not be identified in most people living with hepatitis B and C attending the emergency department; hence, screening beyond risk factors should be considered in hepatitis detection strategies. Emergency department screening is cost-effective for hepatitis C and is a cost-saving strategy for hepatitis B in our setting. These data should inform future updates to clinical guidelines. (c) 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Accelerating the elimination of viral hepatitis for Indigenous peoples
    Cunningham, Chris
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (02): : 93 - 94
  • [32] Elimination of viral hepatitis by 2030: ambitious, but achievable
    Brierley, Rob
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (02): : 88 - 89
  • [33] Global viral hepatitis elimination by the year 2030
    Tjan, Richard
    UNIVERSA MEDICINA, 2016, 35 (03) : 143 - 145
  • [34] Funding the elimination of viral hepatitis: donors needed
    Gore, Charles
    Hicks, Jessica
    Deelder, Wouter
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12): : 843 - 845
  • [35] Viral hepatitis elimination: a challenge, but within reach
    Wang, Helena Hui
    Lau, Esther
    Horton, Richard
    LANCET, 2022, 400 (10348): : 251 - +
  • [36] Joint Society Statement for elimination of viral hepatitis
    Brahm, Javier
    Castera, Laurent
    Hou, Jinlin
    Lindor, Keith
    ANNALS OF HEPATOLOGY, 2017, 16 (01) : 6 - 7
  • [37] VIRAL HEPATITIS Viral hepatitis: progress and promise
    Wood, Natalie J.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2011, 8 (05) : 239 - 239
  • [38] Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update
    Cooke, Graham S.
    Flower, Barnaby
    Cunningham, Evan
    Marshall, Alison D.
    Lazarus, Jeffrey, V
    Palayew, Adam
    Jia, Jidong
    Aggarwal, Rakesh
    Al-Mahtab, Mamum
    Tanaka, Yashuito
    Jeong, Sook-Hyang
    Poovorawan, Kittiyod
    Waked, Imam
    Hiebert, Lindsey
    Khue, Pham M.
    Grebely, Jason
    Alcantara-Payawal, Diana
    Sanchez-Avila, Juan F.
    Mbendi, Charles
    Muljono, David H.
    Lesi, Olufunmilayo
    Desalegn, Hailemichael
    Hamid, Saeed
    de Araujo, Alexandre
    Cheinquer, Hugo
    Onyekwere, Charles A.
    Malyuta, Ruslan
    Ivanchuk, Iryna
    Thomas, David L.
    Pimenov, Nikolay
    Chulanov, Vladimir
    Dirac, Mae Ashworth
    Han, Hannah
    Ward, John W.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (04): : 346 - 365
  • [39] Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update
    Cooke, Graham S.
    Flower, Barnaby
    Cunningham, Evan
    Marshall, Alison
    Lazarus, Jeffrey, V
    Palayew, Adam
    Jia, Jidong
    Aggarwal, Rakesh
    Al-Mahtab, Mamum
    Tanaka, Yashuito
    Jeong, Sook-Hyang
    Poovorawan, Kittiyod
    Waked, Imam
    Hiebert, Lindsey
    Khue, Pham M.
    Grebely, Jason
    Alcantara-Payawal, Diana
    Sanchez-Avila, Juan F.
    Mbendi, Charles
    Muljono, David H.
    Lesi, Olufunmilayo
    Desalegn, Hailemichael
    Hamid, Saeed
    de Araujo, Alexandre
    Cheinquer, Hugo
    Onyekwere, Charles A.
    Malyuta, Ruslan
    Ivanchuk, Iryna
    Thomas, David L.
    Pimenov, Nikolay
    Chulanov, Vladimir
    Dirac, Mae Ashworth
    Han, Hannah
    Ward, John W.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (02): : 346 - 365
  • [40] Hepatitis E Virus; An Underestimated Threat for the Viral Hepatitis Elimination Program
    Pourkarim, Mahmoud Reza
    HEPATITIS MONTHLY, 2022, 22 (01)